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Background: Although many studies have examined the relationship between uric acid (UA) and coronary artery
disease (CAD), whether UA is an independent risk factor contributing to progression of CAD is still controversial.
Whether UA plays a different role in different sexes is also unclear.
Methods: A total of 1116 individuals with suspected CAD were stratified into four groups according to their serum
UA quartiles in total (men and women combined), in men, and in women. The association of UA with coronary
atherosclerosis was assessed by univariable and multivariable logistic regression.
Results: In total and in women, the prevalence of any plaques and significant/severe stenosis was significantly
increased with an increase in quartiles of UA (all P < 0.05). The proportion of triple-vessel disease and left main
artery lesion was highest in the fourth quartile (both p < 0.05). Increasing quartiles of UA were significantly associated
with a coronary artery calcium score (CACS) >10 (all P < 0.01). As UA levels increased in women, the incidence of
double-vessel lesions (p = 0.017) and the proportion of mixed plaques (p = 0.022) were significantly increased. The
proportion of a CACS of 0 in total, in men and women was highest in the first quartile (all P < 0.01). UA was the
strongest predictor of significant stenosis, multivessel disease, and mixed plaques in women (all p < 0.05). UA was
the only risk factor for mixed plaques in total (P = 0.046).
Conclusion: The level of UA was significantly associated with coronary atherosclerosis in women, but not men.
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Calcium scoreBackground
Uric acid (UA) is the main end product of purine catab-
olism [1]. High UA levels are often accompanied by
obesity, hyperlipidemia, hypertension, glucose intoler-
ance, and insulin resistance [2-5], which contribute to
the development of cardiovascular disease. Elevated UA
levels are associated with coronary artery disease (CAD),
independently of traditional CAD risk factors [6,7].* Correspondence: qigx2011@hotmail.com
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reproduction in any medium, provided the orHowever, some studies have suggested that UA is only
considered as a risk marker or an adaptive ascended to
attempt to prevent atherosclerosis [8-10], and this may
be due to its antioxidant properties [11]. Although stud-
ies have examined the relationship between UA and
CAD, whether increased UA is an independent risk fac-
tor that contributes to early CAD is still controversial.
Sex might be an important factor involved in the rela-
tionship between UA and CAD. In a subgroup analysis
of LIFE [12], the relationship between UA and CAD was
significant only in women. A meta-analysis [6] found
that UA was significantly correlated with CAD only in
women. A strong association between UA and cardiac. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Sun et al. BMC Cardiovascular Disorders 2014, 14:101 Page 2 of 16
http://www.biomedcentral.com/1471-2261/14/101events has been observed in both sexes in other studies
[13,14]. Whether UA plays a different role in different
sexes in the progression of CAD is unclear.
Therefore, in this study, we assessed the association
between UA and coronary atherosclerosis in patients
with suspected CAD who underwent 256-detector-row
coronary computed tomographic angiography (CCTA).
We further assessed these associations in sex subgroups.
Methods
Study population
This study included 5150 consecutive individuals
(≥18 years) in China undergoing CCTA and coronary ar-
tery calcium score (CACS) measurements in our institu-
tion from September 2011 to February 2013. CCTA and
measurement of the CACS were performed for the sus-
picion of CAD after clinical assessment (including car-
diac symptoms, risk factors, electrocardiogram changes,
and a positive stress test). Finally, 1116 individuals were
enrolled (Figure 1). All patients gave written inform con-
sent, and the study was approved by the ethics commit-
tee of the First Affiliated Hospital of China Medical
University.
Assessment of CAD risk factors
All patients were systematically asked about their demo-
graphics by professionals. Body weight, height, and blood
pressure were measured. Hypertension was defined as a
previously established diagnosis and/or antihypertensive
medication, systolic blood pressure ≥140 mmHg, and
diastolic blood pressure ≥90 mmHg. Diabetes mellitus
was defined as a previously established diagnosis and/orFigure 1 The path of patients enrollment.antidiabetic treatment, and fasting glucose ≥126 mg/dl. A
family history of CAD was defined as a first-degree male
relative aged <55 years or a first-degree female relative
aged <65 years. Smoking was defined as any cigarette
smoking within 1 year of CCTA. Medication use was re-
corded in detail.
Total cholesterol (TC), triglycerides (TG), high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), creatinine and UA levels were mea-
sured after at least a 12-h fasting period within 7 days of
CCTA. The contents of UA were measured with enzyme
kinetics in all enrolled patients, and it was uniform
throughout the study period.
Acquisition of images
Computed tomography scans were performed using
256-detector-row CCTA (Brilliance; Philips Medical
System, The Netherlands). Individuals with a heart
rate ≥75 beats per minute were treated orally with up to
100 mg metoprolol for several hours (except for contra-
indications of beta-blockers) before CCTA imaging to
achieve a higher image quality. First, after a scout radio-
graph of the chest (lateral and anteroposterior), a non-
contrast CACS scan was performed, and the image
section thickness was 2.5 mm by triggering at a heart
rate depending on the percentage of the R-R interval.
The sections were collected from the level of the carina
and proceeded to the level of the diaphragm. Thereafter,
retrospective electrocardiogram-gated contrast-enhanced
CCTA was performed. The CCTA scan was initiated
20 mm above the level of the left main artery to 20 mm
below the inferior myocardial apex during a single
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bolus of 50–80 ml of iopamidol or iohexol was intraven-
ously injected at 4–5.5 ml/s into the antecubital vein,
followed by 50 ml of saline. A standard scan protocol
was applied, with section collimation of 256 × 0.625 mm,
0.27 s for rotation time, 120 KV tube voltage, and 800–
1100 mA tube current. In all scans, electrocardiogram-
gate dose modulation was used. The electrocardiograms
of individuals were simultaneously collected to allow for
retrospective segmental data reconstruction. The images
of all individuals were initially reconstructed at 75% of
the R-R interval of the cardiac cycle. If motion artefacts
were found, reconstruction of additional phases was per-
formed. The best R-R interval image quality was chosen
for interpretation. The dose range of radiation for CCTA
was estimated to be 10–18 mSv.
Image analysis
All images were analysed separately by two experienced
radiologists and one cardiologist who were blinded to
the patients’ characteristics. Consensus on interpretation
was performed to achieve a final CCTA diagnosis. All
scans were evaluated by a three-dimensional workstation
(Brilliance; Philips Medical Systems). The CACS was
measured using the scoring system previously described
by Agatston et al. [15].
The three reads were permitted to use any/all available
post-processing image reconstruction algorithms, includ-
ing two-dimensional axial or three-dimensional maximal
intensity projection, multiplanar reformat, cross-sectional
analysis, or the volume-rendered technique. A 16-segment
coronary artery tree model [16] was used in the analysis of
coronary arteries. In each coronary segment, plaques were
defined as any tissue structure >1 mm2, which existed ei-
ther within the coronary artery lumen or was adjacent to
the coronary artery lumen, and could be discriminated
from surrounding pericardial tissue, epicardial fat, or the
vessel lumen itself. For evaluating the degree of stenosis,
the coronary lumen was semi-automatically traced at the
maximal stenosis site and was compared with the mean
value of a proximal and distal reference site. The image
quality was evaluated and classified as follows: good, with
no artifact; adequate, with the presence of artifacts but
feasible for evaluating the degree of stenosis and plaque
characteristics; or poor, with the presence of artifacts and
not feasible for evaluating the degree of stenosis and
plaque characteristics. If an image was graded as poor, the
image was not included.
Coronary lesions ≥50 and 70% were defined as signifi-
cant and severe, respectively. Multivessel disease was de-
fined as the presence of stenosis of more than 50% in at
least two vessels. The stenosed coronary vessel of indi-
viduals was further categorized as having one-, two-, and
three-vessel/left main disease. All detected plaques wereclassified as calcified, non-calcified, or mixed. The calci-
fied component of a stenosis was defined as a lesion
with radiodensity greater than the luminal contrast. The
non-calcified component of a stenosis was defined as a
lesion with radiodensity greater than that of neighbour-
ing soft tissue and lower than the luminal contrast. Pla-
ques that contained calcified tissue greater than 75% of
the plaque area were classified as calcified plaques, less
than 25% as non-calcified plaques, and 25–75% as mixed
plaques [17].
Statistical analysis
Baseline characteristics are expressed as absolute counts
and proportions for categorical variables, and as means ±
standard deviations for continuous variables. Continuous
variables were analysed by analysis of variance and cat-
egorical variables were analysed by χ2 test.
The association of UA with coronary atherosclerosis
was assessed by the χ2 test. Univariable and multivariable
logistic regression were used to assess the association of
UA with significant stenosis, multivessel disease, high
CACS, and plaque characteristics. Variables that showed
a P value <0.1 with univariable analysis were applied to
multivariate analysis. All analyses were performed using
SPSS 15.0. The level of significance was set at P < 0.05.
Results
Baseline characteristic baseline characteristics
Among the 1116 patients in the study, 50.7% were men,
and the mean age was 58.05 ± 10.69 years. All individuals
were stratified into four groups according to their UA
quartile, the first quartile:<259 μmmol/l (n = 278); the
second quartile: 259–309 μmmol/l (n = 274); the third
quartile: 310-373 μmmol/l (n = 283) and the fourth quar-
tile: >373 μmmol/l (n = 281). With increasing UA quartiles,
the prevalence of male sex, smoking, and hypertension was
significantly increased (all P < 0.01). Body mass index (BMI)
and TC level were significantly higher (all P < 0.001) and
HDL-C level was significantly lower (P < 0.001, Table 1).
Figure 2 showed the representative view of mixed, non-
calcified and calcified plaque.
Prevalence, characteristics, and the CACS of coronary
artery plaques
Men and women were stratified into four groups according
to their UA quartile. The quartiles of UA in men were the
first quartile: 296 μmmol/l (n = 140); the second quartile:
<296-349 μmmol/l (n = 140); the third quartile: 350-406
μmmol/(n = 144) and the fourth quartile: >406 μmmol/l
(n = 142). The quartiles of UA in women were the first
quartile: <238 μmmol/l (n = 136); the second quartile: 238-
273 μmmol/l (n = 137); the third quartile: 274-326 μmmol/
l(n = 138) and the fourth quartile > 326 μmmol/l (n = 139).
With increasing UA quartiles in total (men and women
Table 1 Baseline characteristics of the all study population according to the quartiles of the serum uric acid













Age(years) 58.05 ± 10.69 58.64 ± 9.19 57.86 ± 9.52 58.14 ± 11.09 57.56 ± 12.6 0.674
Male 566 (50.7) 64 (23.0) 109 (39.8) 170 (60.1) 223 (79.4) <0.001
BMI(kg/m2) 24.99 ± 4.00 23.46 ± 4.24 24.70 ± 3.29 25.83 ± 4.45 25.95 ± 3.38 <0.001
Smoking 279 (25.0) 40 (14.4) 59 (21.5) 89 (31.4) 91 (32.4) <0.001
Family history of CAD 93 (8.3) 27 (9.7) 29 (10.6) 20 (7.1) 17 (6.0) 0.167
Hypertension 639 (42.7) 96 (34.5) 114 (41.6) 135 (47.7) 132 (47.0) 0.005
Diabetes Mellitus 183 (16.4) 45 (16.2) 43 (15.7) 51 (18.0) 44 (15.7) 0.861
LDL-C(mmol/l) 2.95 ± 0.88 2.93 ± 0.79 3.02 ± 1.01 2.94 ± 0.87 2.92 ± 0.87 0.544
HDL-C(mmol/l) 1.19 ± 0.37 1.33 ± 0.34 1.21 ± 0.32 1.13 ± 0.30 1.09 ± 0.46 <0.001
TC(mmol/l) 4.60 ± 1.06 4.61 ± 0.97 4.66 ± 1.22 4.58 ± 1.06 4.56 ± 0.99 0.735
TG(mmol/l) 1.64 ± 1.36 1.29 ± 0.85 1.59 ± 1.29 1.69 ± 1.47 1.98 ± 1.61 <0.001
Creatinine(μmol/l) 78.20 ± 16.32 81.47 ± 16.74 80.09 ± 14.23 74.07 ± 15.38 81.95 ± 19.17 0.121
History of Medication
Aspirin 247 (22.1) 64 (23.0) 57 (20.8) 67 (23.7) 59 (21.0) 0.799
Beta blcker 118 (10.6) 27 (9.7) 26 (9.5) 31 (11.0) 34 (12.1) 0.733
ACEI 62 (5.6) 13 (4.7) 15 (5.5) 17 (6.0) 17 (5.6) 0.880
ARB 68 (6.1) 14 (5.0) 13 (4.7) 20 (7.1) 21 (7.5) 0.417
CCB 145 (13.0) 28 (10.1) 43 (15.7) 42 (14.8) 32 (11.4) 0.144
Statins 94 (8.4) 20 (7.2) 25 (9.1) 30 (10.6) 19 (6.8) 0.330
Antihyperglycemic 107 (9.6) 30 (10.8) 23 (8.4) 29 (10.2) 25 (8.9) 0.750
Insulin 65 (5.8) 18 (6.5) 14 (5.1) 18 (6.4) 15 (5.3) 0.863
Values are mean ± Standard deviation or n (%). The conversion of UA measuring unit: mg/dl = (μmol/l divide by 59.48).
BMI Body Mass Index, CAD Coronary artery disease, LDL-C Low-density lipoprotein Cholesterol, HDL-C High-density lipoprotein Cholesterol, TC Total Cholesterol,
TG Triglycerides, ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker, CCB Calcium Channel Blocker.
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significantly increased (total: 56.8% vs 62.0% vs 70.0% vs
73.0%, P < 0.001; women: 47.1% vs 57.7% vs 59.4% vs
69.8%, p = 0.002, (Figure 3A), significant stenosis were sig-
nificantly increased (total: 25.5% vs 30.3% vs 39.6% vs
40.2%, P < 0.001; women: 16.9% vs 29.2% vs 30.4% vs
33.1%, P = 0.010, Figure 3B), and severe stenosis were sig-
nificantly increased (total: 12.9% vs 18.2% vs 21.9% vs
25.6%, P = 0.001; women: 8.1% vs 16.8% vs 17.4% vs 19.4%,
P = 0.032, Figure 3C).Figure 2 Showed the representative view of mixed, non-calcified plaqThe incidence of double-vessel lesions was only signifi-
cantly increased with UA quartiles in women (9.6% vs
13.1% vs 14.5% vs 23.0%, P = 0.017, Figure 3E). In total
and in women, the proportion of triple-vessel/left main
artery lesions were highest in the fourth quartile (total:
15.8% vs 19.3% vs 26.5% vs 28.8%, P < 0.001; women:
13.2% vs 16.8% vs 24.6% vs 25.2%, P = 0.027, Figure 3F).
The proportion of a CACS of 0 in total, in men, and
in women were lowest in the fourth quartile (total:
64.4% vs 59.1% vs 49.1% vs 46.6%, P < 0.001; men: 55.7%ue.
Figure 3 Relationship with anyplaque (A), significant stenosis (B) and severe stenosis (C), single vessel lesion (D), double vessel lesion
(E) and triple vessel/left main artery lesion (F) across quartile of serum uric acid levels across quartile of serum uric acid levels.
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72.3% vs 60.9% vs 51.8%, P < 0.001, Figure 4A). The in-
creasing quartiles of UA were significantly associated
with a CACS >10 in total (30.6% vs 32.5% vs 41.7% vs
44.5%, P = 0.001) and in women (22.1% vs 24.1% vs
31.2% vs 41.0%, p = 0.002, Figure 4B.). As UA levels in-
creased in women, the proportion of mixed plaques sig-
nificantly increased (21.7% vs 22.7% vs 24.5% vs 30.5%,
P = 0.022, Figure 5C).
Univariate and multivariate logistic regression models
In multivariate analysis for men and women combined,
age, male sex, smoking, hypertension, and diabetes mellitus
(DM) were significantly associated with significant sten-
osis, multivessel disease, and a high CACS (all p < 0.001).
HDL-C level was only significantly associated with signifi-
cant stenosis and multivessel disease (both P ≤ 0.002). UAwas the strongest predictor for significant stenosis, multi-
vessel disease, and a high CACS in univariate analysis (all
P < 0.001), but this association was not apparent after ad-
justment (Table 2).
The same analyses were performed for men and
women (Tables 3 and 4). For men, significant predictors
of significant stenosis were age, hypertension, and HDL-
C levels after adjustment (all p < 0.05). Significant pre-
dictors of multivessel disease were age and hypertension
after adjustment (both P < 0.05). The strongest risk fac-
tors for a high CACS were age and hypertension after
adjustment (both P < 0.05, Table 3). For women, signifi-
cant predictors of stenosis were age, hypertension, DM,
and UA after adjustment (all P < 0.05). Significant pre-
dictors of multivessel disease were age, hypertension,
DM, and UA after adjustment (all P < 0.05). The stron-
gest risk factors for a high CACS were age, hypertension,
AB
Figure 4 Prevalence of coronary artery calcium score = 0 across quartile of serum uric acid levels (A), prevalence of coronary artery
calcium score >10 across quartile of serum uric acid levels (B).
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Table 4).
In total, significant predictors of significant stenosis
were age, male sex, smoking, hypertension, and DM
after adjustment (all P < 0.05). Significant predictors of
non-calcified plaques were age, smoking, hypertension,
DM, and HDL-C levels after adjustment (all P < 0.05).
After adjustment, the strongest risk factors for mixed
plaques were age, male sex, smoking, hypertension, DM,
and UA (all P < 0.05, Table 5). For men, significant pre-
dictors of calcified plaques were age, hypertension, DM,
and HDL-C after adjustment (all P < 0.05). The stron-
gest risk factors for non-calcified plaques were age,
smoking, DM, and HDL-C in univariate and multivari-
ate analysis (all P < 0.05). The strongest risk factors for a
high CACS were age, smoking, and HDL-C levels after
adjustment (all P < 0.05, Table 6). For women, significantpredictors of calcified plaques were age, hypertension,
and DM after adjustment (all P < 0.05). Significant pre-
dictors of non-calcified plaques were age, hypertension,
and HDL-C after adjustment (all P < 0.05). Age, hyper-
tension, DM, and UA were significantly associated with
mixed plaques in univariate and multivariate analysis
(all P < 0.05, Table 7).
Discussion
In this study of individuals with suspected CAD using
256-detector-row CCTA, we analysed the association of
UA with coronary atherosclerosis. We found the follow-
ing findings. 1) Overall and in women, the prevalence of
coronary atherosclerosis, severe stenosis, and triple-vessel/
left main artery lesions of plaques were significantly in-
creased with increasing quartiles of UA. UA was signifi-
cantly associated with double-vessel lesions in women. 2)
Figure 5 Relationship with (A) calcified, noncalcified (B) and mixed (C) across quartile of serum uric acid levels.
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portion of a CACS of 0, but was positively correlated with
the proportion of a CACS >10 overall and in women. The
incidence of mixed plaques was significantly increased
only in women with elevated UA levels. 3) After adjust-
ment, only UA was a significant predictor of significantstenosis, multivessel disease, and mixed plaques in women.
UA was not significantly associated with coronary athero-
sclerosis in men.
Coronary artery angiography (CAG) is the gold stand-
ard for diagnosing CAD, but CAG cannot determine the
characteristics of plaques. CAG would be difficult to use
Table 2 Univariate and multivariate logistic regression models for variables of total population associated with coronary artery lesions and high CACS (n = 1116)
V variable Significant stenosis (>50%) Multivessel disease High CACS (CACS > 100)
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Variable OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P
Age 1.059 (1.046-1.073) <0.001 1.070 (1.054-1.086) <0.001 1.066 (1.052-1.081) <0.001 1.079 (1.062-1.096) <0. 001 1.078 (1.061-1.095) <0.001 1.089 (1.070-1.108) <0.001
Male 2.364 (1.830-3.054) <0.001 2.208 (1.579-3.089) <0.001 2.365 (1.815-3.083) <0.001 2.320 (1.637-3.288) <0.001 2.244 (1.653-3.047) <0.001 2.190 (1.486-3.226) <0.001
BMI 1.028 (0.997-1.060) 0.082 1.010 (0.975-1.047) 0.568 1.027 (0.996-1.060) 0.092 1.010. (0.974-1.047) 0.597 1.017 (0.982-1.052) 0.345 ———————— ———
Smoking 1.789 (1.355-2.364) <0.001 1.835 (1.306-2.578) <0.001 1.739 (1.308-2.310) <0.001 1.866 (1.313-2.653) 0.001 1.854 (1.352-2.542) <0.001 2.294 (1.550-3.395) <0.001
Family history
of CAD
1.076 (0.690-1.678) 0.746 ———————— ——— 1.105 (0.701-1.742) 0.666 ———————— ——— 1.012 (0.598-1.714) 0.964 ———————— ———
Hypertension 2.187 (1.700-2.815) <0.001 1.856 (1.394-2.471) <0.001 2.275 (1.754-2.950) <0.001 1.914 (1.421-2.577) <0.001 2.377 (1.764-3.203) <0.001 1.939 (1.388-2.709) <0.001
DM 2.467 (1.788-3.403) <0.001 1.825 (1.278-2.604) <0.001 2.823 (2.041-3.905) <0.001 2.153 (1.501-3.089) <0.001 2.403 (1.694-3.408) <0.001 1.983 (1.344-2.927) 0.001
LDL-C 0.876 (0.758-1.012) 0.072 1.156 (0.812-1.645) 0.421 0.913 (0.787-1.059) 0.228 ———————— ——— 1.061 (0.900-1.251) 0.482 ———————— ———
HDL-C 0.331 (0.202-0.477) <0.001 0.456 (0.276-0.755) 0.002 0.311 (0.202-0.477) <0.001 0.428 (0.256-0.717) 0.001 0.632 (0.396-1.008) 0.054 0.907 (0.559-1.471) 0.691
TC 1.802 (1.724-1.929) 0.002 0.875 (0.641-1.194) 0.399 1.845 (1.744-1.959) 0.009 1.022 (0.885-1.181) 0.765 0.943 (0.819-1.086) 0.415
TG 0.983 (0.895-1.081) 0.726 ———————— ——— 0.992 (0.901-1.092) 0.863 ———————— ——— 0.889 (0.771-1.024) 0.145 ———————— ———
UA 1.003 (1.002-1.004) <0.001 1.001 (0.999-1.002) 0.535 1.003 (1.002-1.004) <0.001 1.001 (0.999-1.002) 0.564 1.003 (1.001-1.005) <0.001 1.001 (0.999-1.003) 0.205
Creatinine 0.980 (0.857-1.018) 0.120 ———————— ——— 1.240 (0.957-1.417) 0.258 ———————— ——— 0.760 (0.526-1.013) 0.173 ———————— ———
Multivessel disease was defined as the present of stenosis of more than 50% in at lease two vessels.



















Table 3 Univariate and multivariate logistic regression models for variables of male associated with coronary artery lesions and high CACS (n = 566)
V variable Significant stenosis (>50%) Multivessel disease High CACS (CACS > 100)
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Variable OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR(95%CI) P
Age 1.056 (1.039-1.073) <0.001 1.052 (1.034-1.070) <0.001 1.060 (1.043-1.077) <0.001 1.055 (1.037-1.073) <0.001 1.077 (1.057-1.098) <0.001 1.071 (1.050-1.093) <0.001
BMI 0.978 (0.937)1.020 0.296 ———————— ——— 0.979 (0.938-1.022) 0.329 ———————— ——— 0.955 (0.906-1.006) 0.084 0.996 (0.945-1.051) 0.894
Smoking 1.245 (0.889-1.743) 0.203 ———————— ——— 1.298 (0.926-1.820) 0.131 ———————— ——— 1.305 (0.896-1.900) 0.166 ———————— ———
Family history
of CAD
1.274 (0.684-2.375) 0.446 ———————— ——— 1.501 (0.805-2.798) 0.201 ———————— ——— 1.080 (0.539-2.162) 0.828 ———————— ———
Hypertension 1.811 (1.291-2.541) 0.001 1.579 (1.098-2.270) 0.014 1.734 (1.235-2.434) 0.001 1.462 (1.016-2.104) 0.041 2.044 (1.400-2.983) <0.001 1.731 (1.138-2.634) 0.010
DM 1.608 (1.045-2.473) 0.031 1.368 (0.862-2.172) 0.184 1.727 (1.123-2.658) 0.013 1.579 (0.998-2.499) 0.051 1.585 (1.001-2.511) 0.049 1.581 (0.952-2.624) 0.077
LDL-C 0.856 (0.694-1.054) 0.143 ———————— ——— 0.919 (0.746-1.133) 0.430 ———————— ——— 0.986 (0.782-1.243) 0.902 ———————— ———
HDL-C 0.575 (0.317-1.044) 0.069 0.485 (0.236-0.995) 0.048 0.635 (0.350-1.152) 0.135 ———————— ——— 0.435 (0.072-0.797) 0.030 1.676 (0.813-3.453) 0.162
TC 1.764 (1.641)1.911 0.003 0.880 (0.712-1.088) 0.239 1.817 (1.688-1.971) 0.022 0.875 (0.721-1.062) 0.176 0.891 (0.738-1.075) 0.229 ———————— ———
TG 1.868 (1.759-1.994) 0.041 0.939 (0.797-1.106) 0.451 0.874 (0.763-1.001) 0.051 0.998 (0.864-1.152) 0.973 1.754 (1.616-1.924) 0.006 0.926 (0.754-1.137) 0.464
UA 1.000 (0.998-1.002) 0.923 ———————— ——— 1.000 (0.998-1.002) 0.716 ———————— ——— 1.000 (0.998-1.002) 0.960 ———————— ———
Creatinine 1.403 (0.549-3.073) 0.613 ———————— ——— 0.923 (0.238-1.997) 0.588 ———————— ——— 0.574 (0.185-1.236) 0.339 ———————— ———
Multivessel disease was defined as the present of stenosis of more than 50% in at lease two vessels.



















Table 4 Univariate and multivariate logistic regression models for variables of female associated with coronary artery lesions and high CACS (n = 550)
V variable Significant stenosis (>50%) Multivessel disease High CACS (CACS > 100)
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Variable OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P
Age 1.096 (1.069-1.123) <0.001 1.084 (1.055-1.113) <0.001 1.092 (1.068-1.117) <0.001 1.075 (1.049-1.101) <0.001 1.100 (1.068-1.133) <0.001 1.085 (1.049-1.122) <0.001
BMI 1.071 (1.013-1.132) 0.015 1.024 (0.985-1.103) 0.151 1.073 (1.018-1.132) 0.009 1.036 (0.980-1.095) 0.216 1.077 (1.012-1.147) 0.020 1.060 (0.998-1.126) 0.060
Smoking 1.434 (0.723-2.845) 0.303 ———————— ——— 1.317 (0.692-2.504) 0.402 ———————— ——— 1.795 (0.822-3.918) 0.142 ———————— ———
Family history
of CAD
0.978 (0.496-1.932) 0.950 ———————— ——— 0.716 (0.376-1.363) 0.309 ———————— ——— 1.017 (0.440-2.351) 0.969 ———————— ———
Hypertension 3.144 (2.096-4.718) <0.001 2.229 (1.420-3.500) <0.001 3.689 (2.550-5.336) <0.001 2.618 (1.735-3.950) <0.001 3.385 (2.017-5.680) <0.001 2.162 (1.216-3.843) 0.009
DM 4.144 (2.536-6.772) <0.001 2.669 (1.554-4.584) <0.001 4.301 (2.620-7.061) <0.001 2.913 (1.682-5.044) <0.001 4.286 (2.476-7.418) <0.001 2.958 (1.582-5.531) 0.001
LDL-C 1.049 (0.851-1.293) 0.652 ———————— ——— 1.044 (0.863-1.263) 0.654 ———————— ——— 1.381 (1.078-1.769) 0.011 2.090 (0.868-5.036) 0.100
HDL-C 0.309 (0.158-0.602) <0.001 0.462 (0.219-0.977) 0.430 0.344 (0.192-0.618) <0.001 0.642 (0.336-1.227) 0.180 0.265 (0.112-0.629) 0.003 0.327 (0.118-0.908) 0.032
TC 1.056 (0.878-1.271) 0.561 ———————— ——— 1.054 (0.890-1.247) 0.544 ———————— ——— 1.236 (0.991-1.541) 0.060 0.776 (0.346-1.741) 0.776
TG 1.190 (0.994-1.424) 0.058 1.043 (0.852-1.276) 0.684 1.338 (1.103-1.623) 0.003 1.131 (0.913-1.401) 0.259 1.094 (0.897-1.334) 0.374 ———————— ———
UA 1.214 (1.101-1.407) 0.002 1.004 (1.001-1.007) 0.011 1.115 (1.103-1.134) <0.001 11.131(0.913-1.401)
1.003(1.000-1.006)
<0.001 1.005 (1.001-1.008) 0.004 1.001 (0.997-1.004) 0.793
Creatinine 1.835 (0.511-3.164) 0.535 ———————— ——— 0.714 (0.138-2.227) 0.407 ———————— ——— 0.925 (0.238-2.764) 0.868 ———————— ———
Multivessel disease was defined as the present of stenosis of more than 50% in at lease two vessels.



















Table 5 Univariate and multivariate logistic regression models for variables of total population associated with calcified, non-calcified and mixed plaque (n = 1116)
V variable Calcified plaque Non-calcified plaque Mixed plaque
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Variable OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P
Age 1.071 (1.057-1.086) <0.001 1.052 (1.023-1.081) <0.001 1.028 (1.016-1.040) <0.001 1.034 (1.021-1.047) <0.001 1.056 (1.042-1.069) <0.001 1.066 (1.051-1.081) <0.001
Male 2.022 (1.579-2.590) <0.001 2.282 (1.662-3.132) <0.001 1.666 (1.315-2.111) <0.001 1.249 (0.925-1.686) <0.147 2.328 (1.806-3.000) <0.001 2.002 (1.445-2.774) <0.001
BMI 1.017 (0.987-1.048) 0.276 ———————— ——— 1.045 (1.012-1.080) 0.008 1.023 (0.988-1.058) 0.202 1.021 (0.991-1.053) 0.173 ———————— ———
Smoking 1.428 (1.084-1.881) 0.011 1.224 (1.036-1.467) 0.043 1.707 (1.297-2.246) <0.001 1.729 (1.258-2.376) 0.001 2.171 (1.645-2.864) <0.001 2.336 (1.669-3.270) <0.001
Family history
of CAD
0.825 (0.527-1.293) 0.402 ———————— ——— 1.183 (0.773-1.810) 0.438 ———————— ——— 1.022 (0.655-1.592) 0.925 ———————— ———
Hypertension 2.180 (1.703-2.792) <0.001 1.832 (1.393-2.409) <0.001 1.579 (1.244-2.005) <0.001 1.319 (1.017-1.711) 0.037 2.090 (1.627-2.683) <0.001 1.810 (1.367-2.395) <0.001
DM 2.538 (1.839-3.503) <0.001 2.065 (1.524-2.265) <0.001 1.924 (1.390-2.665) <0.001 1.510 (1.070-2.130) 0.019 2.386 (1.731-3.291) <0.001 1.917 (1.346-2.730) <0.001
LDL-C 1.669 (0.930-1.227) 0.348 ———————— ——— 0.945 (0.826-1.082) 0.945 ———————— ——— 0.981 (0.852-1.129) 0.786 ———————— ———
HDL-C 0.851 (0.601-1.206) 0.365 ———————— ——— 0.347 (0.235-0.512) <0.001 0.493 (0.322-0.757) 0.001 0.504 (0.338-0.752) 0.001 0.763 (0.501-1.164) 0.210
TC 1.009 (0.899-1.132) 0.878 ———————— ——— 0.930 (0.831-1.041) 0.208 ———————— ——— 0.905 (0.803-1.020) 0.103 ———————— ———
TG 0.998 (0.912-1.093) 0.969 ———————— ——— 1.113 (1.009-1.228) 0.033 1.032 (0.933-1.140) 0.542 1.044 (0.954-1.141) 0.348 ———————— ———
UA 1.003 (1.001-1.004) <0.001 1.002 (0.998-1.003) 0.244 1.003 (1.002-1.004) <0.001 1.001 (0.999-1.002) 0.113 1.004 (1.002-1.005) <0.001 1.002 (1.001-1.003) 0.046
Creatinine 1..020 (1.005-1.036) 0.005 0.823 (0.422-1.329) 0.201 1.033 (0.894-1.086) 0.165 ———————— ——— 1.157 (0.811-1.425) 0.148 ———————— ———



















Table 6 Univariate and multivariate logistic regression models for variables of male associated with calcified, non-calcified and mixed plaque (n = 566)
V variable Calcified plaque Non-calcified plaque Mixed plaque
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Variable OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P
Age 1.069 (1.051-1.088) <0.001 1.068 (1.049-1.087) <0.001 1.018 (1.003-1.033) 0.016 1.024 (1.008-1.040) 0.003 1.048 (1.032-1.064) <0.001 1.056 (1.038-1.075) <0.001
BMI 0.979 (0.939-1.021) 0.315 ———————— ——— 1.009 (0.969-1.051) 0.664 ———————— ——— 0.986 (0.946-1.027) 0.500 ———————— ———
Smoking 1.041 (0.745-1.456) 0.812 ———————— ——— 1.484 (1.058-2.082) 0.022 1.709 (1.194-2.447) 0.003 1.597 (1.140-2.237) 0.007 2.258 (1.548-3.294) <0.001
Family history
of CAD
0.771 (0.409-1.455) 0.422 ———————— ——— 1.409 (0.742-2.678) 0.295 ———————— ——— 1.488 (0.797-2.776) 0.212 ———————— ———
Hypertension 1.745 (1.246-2.445) 0.001 1.522 (1.051-2.204) 0.026 1.291 (0.922-1.808) 0.137 ———————— ——— 1.533 (1.095-2.146) 0.013 1.411 (0.978-2.036) 0.066
DM 1.672 (1.086-2.575) 0.020 1.646 (1.027-2.637) 0.038 1.902 (1.209-2.991) 0.005 1.660 (1.043-2.642) 0.033 1.763 (1.144-2.716) 0.010 1.501 (0.942-2.393) 0.088
LDL-C 1.167 (0.948-1.436) 0.145 ———————— ——— 0.932 (0.757-1.146) 0.503 ———————— ——— 0.954 (0.775-1.173) 0.655 ———————— ———
HDL-C 0.219 (0.094-0.344) 0.007 0.358 (0.169-0.547) 0.016 0.489 (0.271-0.882) 0.018 0.455 (0.248-0.832) 0.011 0.478 (0.261-0.874) 0.017 0.387 (0.200-0.749) 0.005
TC 1.058 (0.900-1.244) 0.496 ———————— ——— 0.970 (0.825-1.141) 0.717 ———————— ——— 0.851 (0.719-1.006) 0.059 0.946 (0.785-1.140) 0.561
TG 0.893 (0.787-1.013) 0.080 1.046 (0.925-1.182) 0.476 1.092 (0.967-1.233) 0.158 ———————— ——— 0.990 (0.890-1.102) 0.855 ———————— ———
UA 0.999 (0.998-1.001) 0.601 ———————— ——— 1.001 (0.999-1.003) 0.232 ———————— ——— 1.001 (0.999-1.003) 0.498 ———————— ———
Creatinine 1.061 (0.777-1.321) 0.543 ———————— ——— 1.980 (0.860-4.522) 0.126 ———————— ——— 0.631 (0.483-1.376) 0.194 ———————— ———



















Table 7 Univariate and multivariate logistic regression models for variables of female associated with calcified, non-calcified and mixed plaque (n = 550)
V variable Calcified plaque Non-calcified plaque Mixed plaque
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Variable OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P
Age 1.101 (1.075-1.127) <0.001 1.083 (1.056-1.111) <0.001 1.057 (1.036-1.078) <0.001 1.048 (1.026-1.070) <0.001 1.101 (1.074-1.128) <0.001 1.086 (1.058-1.115) <0.001
BMI 1.041 (0.991-1.093) 0.110 ———————— ——— 1.073 (1.018-1.131) 0.008 1.047 (0.992-1.106) 0.098 1.038 (0.987-1.090) 0.145 ———————— ———
Smoking 1.101 (0.557-2.177) 0.782 ———————— ——— 1.259 (0.670-2.366) 0.474 ———————— ——— 1.702 (0.877-3.302) 0.116 ———————— ———
Family history
of CAD
0.943 (0.494-1.800) 0.859 ———————— ——— 1.076 (0.599-1.933) 0.806 ———————— ——— 0.712 (0.346-1.464) 0.355 ———————— ———
Hypertension 3.078 (2.101-4.508) <0.001 2.216 (1.453-3.380) <0.001 1.991 (1.411-2.810) <0.001 1.506 (1.037-2. 188) 0.032 3.503 (2.340-5.244) <0.001 2.720 (1.759-4.206) <0.001
DM 4.093 (2.513-6.665) <0.001 2.845 (1.666-4.858) <0.001 1.868 (1.161-3.006) 0.010 1.287 (0.772-2.146) 0.333 3.383 (2.076-5.513) <0.001 2.192 (1.281-3.750) 0.004
LDL-C 1.132 (0.930-1.379) 0.216 ———————— ——— 1.046 (0.870-1.257) 0.633 ———————— ——— 1.186 (0.967-1.455) 0.101 ———————— ———
HDL-C 0.693 (0.404-1.188) 0.182 ———————— ——— 0.358 (0.206-0.622) <0.001 0.486 (0.272-0.870) 0.015 0.965 (0.596-1.561) 0.884 ———————— ———
TC 1.104 (0.926-1.315) 0.270 ———————— ——— 0.982 (0.834-1.156) 0.824 ———————— ——— 1.157 (0.965-1.388) 0.115 ———————— ———
TG 1.202 (1.005-1.438) 0.044 1.111 (0.919-1.343) 0.277 1.111 (0.941-1.312) 0.215 ———————— ——— 1.112 (0.937-1.320) 0.224 ———————— ———
UA 1.004 (1.002-1.007) 0.001 1.001 (0.998-1.434) 0.393 1.004 (1.001-1.006) 0.002 1.001 (0.998-1.004) 0.500 1.004 (1.002-1.007) 0.001 1.003 (0.001-1.006) 0.015
Creatinine 1.119 (0.866-1.288) 0.274 ———————— ——— 1.026 (0.687-1.537) 0.253 ———————— ——— 0.498 (0.173-2.051) 0.341 ———————— ———
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http://www.biomedcentral.com/1471-2261/14/101as a general screening tool in China because of its highly
invasive nature, radiation exposure, and cost. The tech-
nique of 256-detector-row CCTA with a shorter scan-
ning time can improve image quality and it has a
minimal radiation dose [18]. Use of CCTA in a general
routine health evaluation is not discouraged [19]. There-
fore, healthy subjects were not included in our study.
We enrolled those patients with suspected CAD who
needed to have a CCTA examination while undergoing
a clinician’s assessment. CCTA is a screening tool for
assessing individuals of suspected CAD, and is the most
feasible and effective method to reflect widespread epi-
demiology and characteristics of early CAD in China.
Many studies have assessed the association of UA with
CAD and clinical outcome, but the results were still
controversial. Kocaman et al. found that UA was an in-
dependent predictor of CAD in individuals undergoing
CAG [20]. However, the Framingham studies showed
that UA was not an independent predictor of CAD and
cardiovascular outcomes [21], and similar results were
found in the ARIC study [22] and a study by Strask et al.
[23]. Carotid intima-media thickness (C-IMT) measured
by ultrasonography is widely used as a surrogate marker
for atherosclerotic disease and directly associated with
increased risk of cardiovascular disease. The higher UA
levels were associated with higher C-IMT independent
from hypertension, UA levels were independently associ-
ated with C-IMT [24,25]. But a study shown UA was not
significantly associated with C-IMT, UA was associated
with Internal carotid artery resistive index in hyperten-
sive women, suggesting that there might gender-related
differences in the relationship between UA and vascular
damage [26]. In our study, although the prevalence and
degree of plaques were significantly increased with UA
overall, UA was not a significant independent predictor.
Several studies have shown conflicting results on the
association between UA and CAD in men and women.
Some studies have demonstrated that UA was an inde-
pendent risk factor for CAD in both sexes [13,14]. A
high UA level was found to be an independent pre-
dictor for cardiovascular mortality in men [27]. In the
LIFE study, the significant association of UA with CAD
was found only in women [12]. Cardiovascular death
was increased by 1.77 times in men and 3.0 times in
women in the upper UA quartile in the NHANES I
study [28]. A previous study reported that UA levels
only in women were associated with CAD [29]. Our
study supported the opinion that UA was an independ-
ent predictor for the prevalence and severity of early
CAD only in women.
Previous reports have proven the highly predictive
value of the CACS on cardiovascular outcomes [30,31].
Some studies have shown a significant relationship be-
tween UA and the CACS [32-34], and a recent studyshowed that UA was an independent factor predictive of
the CACS [34]. However, some studies did not support
these previous findings [7,35]. In our study, we found
that UA was significantly associated with the CACS, but
UA was not an independent risk factor for a high CACS
overall, in men and women. The relationship between
UA and CACS, and the concrete mechanisms are still
unclear. Few studies have focused on the role of UA in
characterization of plaques as shown by CCTA. One
study showed that UA was only significantly associated
with calcified plaques [36]. In our study, only UA was an
independent predictor for mixed plaques overall and in
women. The relationship between UA and mixed pla-
ques was likely caused by the female subgroup. Many
studies have indicated that mixed plaques might be the
biggest risk of plaque rupture, causing acute coronary
events [37,38]. This may be a rational explanation for
why high UA level was associated with an increase in
the prevalence of mixed plaques in women, which causes
an increase in the incidence of adverse cardiovascular
outcomes. However, there are too few studies on the re-
lationship between UA and plaque characteristics, and
further studies are required.
UA is a general antioxidant in the body, and a high
UA level is suggestive of oxidative stress, endothelial
dysfunction, and slow coronary artery flow [39,40]. UA
promotes vascular smooth muscle proliferation, and
upregulates the expression of monocyte chemoattractant
protein-1 and platelet-derived growth factor [41]. Endo-
thelial dysfunction is an important step in the develop-
ment of atherosclerosis. A recent study showed a
relationship between UA and endothelial dysfunction of
coronary microvasculature only in women [42], which
may be a possible explanation for the significant associ-
ation between UA and CAD in women. The underlying
mechanisms behind the significant relationship between
UA and CAD in women but not men remain enigmatic.
Our study suggests that UA plays an important role in
coronary atherosclerosis in women.
The incidence of cardiovascular events is still high
after controlling for traditional risk factors. Our study
suggests that UA should be considered as an additional
risk factor beyond traditional factors for CAD in women.
However, a randomized study still needs to be per-
formed to determine the effect of UA-lowering therapies
on cardiovascular prevention. In the GREACE study, de-
creased UA levels by atorvastatin were independently
correlated with a reduced risk of cardiovascular out-
comes [43]. The LIFE study showed an association be-
tween UA and cardiovascular events in hypertensive
women, the unique results may be due in part to the
specific feature of reduction of UA by losartan, but it did
not mean that the beneficial effects observed with losar-
tan were contributed to decreasing UA levels [12]. The
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http://www.biomedcentral.com/1471-2261/14/101relationship between low UA level and cardiovascular
benefits is still uncertain. Therefore, further research
should be performed to assess the direct relationship be-
tween decreasing UA level and cardiovascular benefits.
There were several limitations to our study. All indi-
viduals were suspected of having CAD, we mainly
want to explore the relationship between UA and early
CAD in the study. Patients with known CAD may im-
plement lifestyle modifications and drugs intervention
to some extent, the real relationship between UA and
CAD may be influenced by those confounding factors,
So, we exclude the patients who had known CAD.
There was a possible selection bias and this could
restrict generalizability of our results to similar care
settings. Unmeasured confounders may have affected
our results. In our study, almost 90% of women were
post-menopausal and few women received oestrogen-
replacement therapy. Therefore, we did not analyse
the potential effects of oestrogen on the relationship
between UA and CAD. In cross-sectional analysis, we
did not find a longitudinal relationship between UA
and cardiovascular outcomes. In spite of these limita-
tions, the strong association of UA with early CAD in
women had an important clinical significance in pre-
vention and treatment of CAD. Longitudinal studies
are required to confirm the association of UA with
CAD and cardiovascular outcome.Conclusion
UA is a significant predictor of significant stenosis, mul-
tivessel disease, and mixed plaques in women. Import-
antly, our study suggests that UA level may play an
important role in the occurrence and development of
coronary atherosclerosis in women but not men.
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